Uncategorized
No benefit to bevacizumab in advanced AMD
NEW YORK (Reuters Health) - Intravitreal bevacizumab does not benefit patients with advanced
neovascular age-related macular degeneration (AMD) and very poor vision, according to a new 21-patient
study.